RVL Pharmaceuticals plc
RVLP · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.05 | 0.04 | -0.01 |
| FCF Yield | -38.34% | -77.69% | 5.78% | 8.07% |
| EV / EBITDA | -3.14 | -1.09 | -8.77 | 8.92 |
| Quality | ||||
| ROIC | -41.26% | -63.23% | -18.32% | 0.91% |
| Gross Margin | 80.98% | 79.33% | 88.14% | 53.49% |
| Cash Conversion Ratio | 0.73 | 0.84 | -0.22 | -0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.44% | -58.22% | -52.78% | -0.78% |
| Free Cash Flow Growth | 31.77% | -490.94% | -51.05% | -11.63% |
| Safety | ||||
| Net Debt / EBITDA | -0.36 | -0.10 | -2.64 | 2.91 |
| Interest Coverage | -14.69 | -20.04 | -15.08 | 0.22 |
| Efficiency | ||||
| Inventory Turnover | 12.06 | 4.32 | 1.80 | 5.24 |
| Cash Conversion Cycle | -40.40 | -252.01 | -102.36 | 108.66 |